6 October 2025
Catalyzing discovery in oncology and diabetes: How sharing an inhibitor targeting the SOS1-RAS axis generated new insights in disease pathology
The recording of our September 25 opnMe seminar is now available for streaming. Explore how the SOS1 inhibitor BI-3406 has unlocked new therapeutic possibilities in cancer and diabetes thanks to opnMe, Boehringer Ingelheim’s open innovation platform.
BI-3406 sparked tremendous interest, resulting in over 100 research proposals. Six innovative projects were ultimately selected for funding. In this seminar, Boehringer Ingelheim’s Marco Hofmann and Ana Puhl share insights into the evaluation and collaboration process. Two of the winners, Matthew Sale and Ioannis Serafimidis, present their findings on the potential of SOS1 inhibition in cancer and diabetes1, respectively.
Start streaming now and find inspiration for your own research.
Subscribe to our newsletter to stay updated on our regular additions to opnMe.com.
About opnMe:
opnMe.com, the open science portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. Our molecules are provided to the scientific community either free of charge as “Molecules to Order” or applied for via scientific research submissions as “Molecules for Collaboration”. With our “opn2EXPERTS” and “techMATCH” programs, we enlist scientific advice on key scientific topics to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our "opn2TALENTS" postdoc grants at one of our research sites offer opportunities for high-level talents to propose innovative approaches for precisely defined scientific questions.
About opnMe online seminars:
We invite you to watch the recordings of our previous opnMe online seminars that focus on other molecules from opnMe:
- GR agonist: How our glucocorticoid receptor agonist impacted pancreatic cancer research
- CatC: Novel roles of Cathepsin C in human disease
- MMP-13 antagonist: Assessing MMP-13 functions in osteoarthritis and aortic aneurysm
- BCL6 degrader: Elucidating the mechanism of small molecule induced protein degradation
Reference:
- Papadimitropoulou A., Charalampous C., Kogionou P., Reinhardt D., Sonntag J., Gavalas A., Hofmann M. H., Erlmann P., Franti M., Doerr J., Klein T., Willis G. R., Serafimidis I. Pharmacological targeting of SOS1-RAS interaction triggers pancreatic β-cell proliferation and sustainably reverses diabetic hyperglycemia. bioRxiv 2025, .06.03.657628. DOI: 10.1101/2025.06.03.657628.